Rapid Therapeutic Science Laboratories, Inc. (RTSL) EPS (Basic) (2016 - 2023)
Rapid Therapeutic Science Laboratories' EPS (Basic) history spans 8 years, with the latest figure at $0.01 for Q2 2023.
- For Q2 2023, EPS (Basic) rose 310.27% year-over-year to $0.01; the TTM value through Jun 2023 reached $0.01, up 101.54%, while the annual FY2022 figure was -$0.23, 39.47% up from the prior year.
- EPS (Basic) for Q2 2023 was $0.01 at Rapid Therapeutic Science Laboratories, down from $0.02 in the prior quarter.
- Across five years, EPS (Basic) topped out at $0.1 in Q4 2019 and bottomed at -$0.37 in Q4 2021.
- The 5-year median for EPS (Basic) is -$0.03 (2022), against an average of -$0.05.
- The largest annual shift saw EPS (Basic) crashed 3465.63% in 2021 before it skyrocketed 310.27% in 2023.
- A 5-year view of EPS (Basic) shows it stood at $0.1 in 2019, then crashed by 110.0% to -$0.01 in 2020, then crashed by 3600.0% to -$0.37 in 2021, then surged by 102.7% to $0.01 in 2022, then grew by 0.0% to $0.01 in 2023.
- Per Business Quant, the three most recent readings for RTSL's EPS (Basic) are $0.01 (Q2 2023), $0.02 (Q1 2023), and $0.01 (Q4 2022).